Benzinga | Apr 29, 2021 07:38AM EDT

Junshi Biosciences And Coherus To Present Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data At 2021 ASCO Annual Meeting Jun. 6

Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021. The abstract has also been selected for ASCO's official press program.



Details regarding the plenary session and abstract publication are as follows:

JUPITER-02: Randomized, double-blind, phase 3 study ofTitle: toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)Abstract #: LBA2Presentation: Plenary Session, June 6, 2021, 1:00 p.m. ? 4:00 p.m. Eastern Daylight TimePublication: June 3, 2021, 5:00 p.m. Eastern Daylight Time

"We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO's plenary session, which traditionally features high-impact studies," said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. "Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited."



In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer, and hepatobiliary malignancies.